Browsing Tag
obesity therapeutics
2 posts
One pen, four doses, one month: Eli Lilly brings Zepbound KwikPen to Ro’s telehealth platform at $299
Eli Lilly (LLY) partners with Ro to launch the FDA-approved Zepbound KwikPen nationwide. What the $299 self-pay device means for the GLP-1 race. Read more.
Can GLP‑1 drugs tackle Alzheimer’s? Novo Nordisk’s setback raises doubts
Can Novo Nordisk challenge Eli Lilly’s GLP-1 lead with Alzheimer’s data? A crucial trial may redefine the future of semaglutide and reshape investor sentiment.